CTOs on the Move

Blue Cross and Blue Shield of Illinois

www.bcbsil.com

 
Blue Cross and Blue Shield Plans in Illinois, Montana, New Mexico, Oklahoma, Texas and several subsidiaries are part of the largest customer-owned health benefits company in the United States and fourth largest overall. We offer a full range of managed care programs for individuals, families, employer groups and Medicare beneficiaries. And we focus on improving the health and wellness of our members and communities by: • offering a variety of health insurance and wellness products to employers and individuals • keeping our focus local • participating in our communities in meaningful ways such as Blue Corps employee volunteer program and ...
  • Number of Employees: 5K-10K
  • Annual Revenue: > $1 Billion
  • www.bcbsil.com
  • 300 East Randolph Street
    Chicago, IL USA 60601
  • Phone: 866.514.8044

Executives

Name Title Contact Details
Michael Viton
Director Cyber Defense Profile
Mark Biersdorf
Business Information Security Officer Profile

Similar Companies

Maat Nutritionals

Maat Nutritionals is a Los Angeles, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

BHE

BHE is an independent health analytics company with over two decades of experience in designing and conducting research that assesses the value of medical technologies.

Tracon Pharmaceuticals

Tracon Pharmaceuticals, is a biopharmaceutical company that licenses, develops, and commercializes targeted therapies for cancer and age-related macular degeneration. The current pipeline takes advantage of established platform technologies to block novel pathways implicated in cancer growth and angiogenesis.

DSM Pharmaceutical Products

DSM is active worldwide in life science products, performance materials and industrial chemicals. The group has annual sales of close to EUR 5.6 billion and employs about 18,500 people at more than 200 sites across the world. DSM ranks among the global

Zogenix

Zogenix is a global pharmaceutical company committed to developing and commercializing therapies with the potential to transform the lives of patients and their families living with rare diseases. The company has two late-stage development programs underway: FINTEPLA® (ZX008, fenfluramine oral solution) for the treatment of seizures associated with Dravet and Lennox-Gastaut syndromes, two rare and often-catastrophic childhood-onset epilepsies, and MT1621, a novel substrate enhancement therapy for the treatment of a rare genetic disorder called TK2 deficiency.